Roche Holding Ltd · SIX:RO
Roche — HY 2021 Earnings Presentation
198 slides from Roche's earnings presentation, Jul 22, 2021
Slide 1: Roche logo
Slide 2: Roche HY 2021 results
Roche HY 2021 results Basel, 22 July 2021
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 4: Group
Group Severin Schwan Chief Executive Officer
Slide 5: HY 2021 performance, Outlook
HY 2021 performance Outlook 5
Slide 6: HY 2021: Strong start into the year
HY 2021: Strong start into the year • Group sales up +8% – Diagnostics with >50% sales growth, supported by strong recovery of base business – Pharma back to growth in Q2, strong performance of new products (capturing >50% of Pharma sales) • Core EPS up +6%, Operating Free Cash Flow +71% • Good deve
Slide 7: Responding quickly and broadly to the pandemic
Responding quickly and broadly to the pandemic Collaboration with Atea on Positive Ph II interim AT-527 development of AT-527 analysis in hospitalized Pharma Collaboration with Regeneron on FDA EUA granted in mild- EU CHMP scientific Positive Ph III (RECOVERY) casirivimab/imdevimab global supply mod
Slide 8: HY 2021: Strong Diagnostics Division driving Group sales growth
HY 2021: Strong Diagnostics Division driving Group sales growth HY 2021 HY 2020 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 21.7 23.2 -7 -3 Diagnostics Division 9.0 6.1 49 51 Roche Group 30.7 29.3 5 8 CER=Constant Exchange Rates 8
Slide 9: HY 2021: Group sales growth recovery
HY 2021: Group sales growth recovery 16% 14%* 14% 13% 12% 10% 9% 9% 8% 8% 7% 7% 7% 7% 6% 6% 6% 6% 6% 6% 6% 6% 5% 5% 7% 8% 4% 6% 4% 5% 5% 4% 4% 4% 4% 3% 2% 3% 3% 1% 1% 0% -2% -4% -4% -6% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 13 13 13 13
Slide 10: HY 2021: New products with continued momentum
HY 2021: New products with continued momentum and strong growth in Diagnostics CHFm % of Pharma Sales CHFm +8% at CER 12,000 51% 11,000 +2,580 +3,058 10,000 38% -402 9,000 -957 8,000 28% 7,000 6,000 -2,847 5,000 20% 4,000 30,713 29,281 3,000 2,000 1,000 0 HY 2018 HY 2019 HY 2020 HY 2021 HY 2020 Phar
Slide 11: HY 2021: Normalization of healthcare systems ongoing
HY 2021: Normalization of healthcare systems ongoing Pandemic continues to impact business dynamics % CER 1st wave 2nd wave 3rd wave +60% +50% +55% +48% Pharmaceuticals +50% • Some normalization of healthcare systems, not yet +40% +32% +28% +40% back to pre COVID-19 levels +30% +25% • Biosimilar imp
Slide 12: HY 2021: Good growth of Core EPS
HY 2021: Good growth of Core EPS Core operating profit Core EPS Operating free cash flow 24.6% 26.4% % of sales 40.6% 40.2% 17.2% 37.9% +6% at CER +71% at CER +4% at CER CHFbn CHF CHFbn 8.1 10.56 11.7 11.12 12.4 10.44 11.8 7.5 5.0 HY 2019 HY 2020 HY 2021 HY 2019 HY 2020 HY 2021 HY 2019 HY 2020 HY 20
Slide 13: HY 2021 performance, Outlook
HY 2021 performance Outlook 13
Slide 14: Continuing to invest in innovation in Pharma and Diagnostics
Continuing to invest in innovation in Pharma and Diagnostics Assets in Ph III & registration at all time high Diagnostics major systems launches 18 ePlex System cobas® 58001 cobas® pure 2 14 3 13 2 11 2 3 1 9 5 4 2 4 4 1 1 1 1 1 cobas® pro (high throughput) cobas® pulse1 1 8 1 5 5 5 NMEs 3 HY 2017 H
Slide 15: 2021 outlook confirmed
2021 outlook confirmed Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID
Slide 16: Pharmaceuticals Division
Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals
Slide 17: HY 2021: Pharmaceuticals Division sales
HY 2021: Pharmaceuticals Division sales Sales still impacted by COVID-19 and biosimilars HY 2021 HY 2020 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 21,671 23,202 -7 -3 United States 10,802 12,464 -13 -8 Europe 4,485 4,190 7 4 Japan 1,808 1,908 -5 0 International 4,576 4,640 -1 2 CER=Cons
Slide 18: HY 2021: Pharmaceuticals Division R&D investment
HY 2021: Pharmaceuticals Division Continued investments into R&D to drive future growth HY 2021 2021 vs. 2020 CHFm % sales CER growth Sales 21,671 100 -3% Royalties & other op. inc. 1,372 6.3 34% Cost of sales -3,882 -17.9 -4% M&D -2,962 -13.7 -6% R&D -5,883 -27.1 19% G&A -754 -3.5 -2% Core operatin
Slide 19: HY 2021: Continued portfolio rejuvenation
HY 2021: Continued portfolio rejuvenation >50% of sales from new products* Ronapreve n/a Ocrevus 23% Hemlibra 45% Tecentriq 29% Evrysdi n/a Actemra / RoActemra 17% Kadcyla 19% Alecensa 20% Phesgo n/a Perjeta 5% Enspryng n/a Gazyva 8% Polivy 17% Xolair -1% Lucentis -3% US Esbriet -3% Xofluza n/a Euro
Slide 20: HY 2021: Oncology still impacted by biosimilars & COVID-19
HY 2021: Oncology still impacted by biosimilars & COVID-19 YoY CER growth HER2 franchise Phesgo • Kadcyla (+19%) with growth in all regions due to adjuvant BC HER2 franchise Herceptin Perjeta (+5%) -8% • Perjeta (+5%) growth cannibalized by Phesgo launch Kadcyla (+19%) Avastin Avastin -40% • Phesgo:
Slide 21: Tecentriq overview
Tecentriq overview: Growth driven by first-in-class indications Landmark results in adjuvant NSCLC presented and filed CHFm YoY CER growth Tecentriq Q2 update 900 +26% +31% Lung franchise (NSCLC, SCLC) 800 +49% +35% • EU: Growth driven by 1L SCLC 700 +99% +54% 600 +136% • EU: 1L PDL1+ NSCLC (IMpower
Slide 22: Hemophilia A franchise: Hemlibra growing strongly
Hemophilia A franchise: Hemlibra growing strongly 29% US/EU-5 patient share reached CHFm YoY CER growth 800 Hemophilia Q2 update +58% 700 +33% • US/EU: Gaining market share in non-inhibitors despite +45% +57% some COVID-19 impact 600 +146% 500 +313% +59% • #1 prescribed prophylaxis in the US for peo
Slide 23: Immunology franchise remains impacted by COVID-19
Immunology franchise remains impacted by COVID-19 CHFm YoY CER growth Immunology Q2 update 2,500 Actemra (+12%) +7% +2% +1% +7% • FDA grants EUA for COVID-19 treatment in hospitalized patients 2,000 • Remains leading RA monotherapy in EU-5; shift from IV to SC 1,500 Esbriet (+1%) 1,000 • COVID-19 im
Slide 24: MS franchise: Ocrevus US market share increases
MS franchise: Ocrevus total US market share increases to 28% MS late stage development programs progressing well CHFm YoY CER growth 1,500 Q2 update +37% +16% +31% • US showing recovery as vaccination roll-out progresses, but 1,250 +55% +38% +10% COVID-19 impact still felt +12% 1,000 +59% +48% • Hig
Slide 25: SMA franchise: Strong US and EU launches
SMA franchise: Strong US and EU launches >1,800 US patients (approaching 20% total share) after <11 months Broad uptake across all patient types in the US Ph III (RAINBOWFISH) interim results: Patients treated with all SMA types CHOP-INTEND scores in presymptomatic babies with SMA (n=5) treated for
Slide 26: Ophthalmology franchise: PDS and faricimab US filings completed
Ophthalmology franchise: PDS and faricimab US filings completed PDS: New Ph III with 36-week dosing interval initiated Port delivery system Faricimab (PDS) (anti-VEGF/Ang-2 biMab) • Ph III (ARCHWAY) data in nAMD show more than 90% of patients • Ph III (YOSEMITE & RHINE) results in DME positive with
Slide 27: Pharma: Strong short- and mid-term news flow
Pharma: Strong short- and mid-term news flow Diversifying the late stage pipeline & setting new standards of care 12 new Ph III studies initiated in H1 Strong news flow ahead (data readout) New to Phase III in Q1 tiragolumab (SKY-4) in 2L cervical cancer Kadcyla + Tecentriq (KATE 3) in 2L+ HER2+ PDL
Slide 28: 2021: Key late-stage news flow
2021: Key late-stage news flow* Compound Indication Milestone Xofluza Healthy patients; High risk patients; Post exposure EU approval Evrysdi SMA type 1/2/3 EU approval faricimab DME/nAMD US/EU joint filing (DME+AMD) Regulatory Tecentriq 1L PDL1+ NSCLC EU approval Venclexta + azacitidine 1L unfit AM
Slide 29: Diagnostics Division
Diagnostics Division Thomas Schinecker CEO Roche Diagnostics
Slide 30: HY 2021: Diagnostics Division sales
HY 2021: Diagnostics Division sales Very strong growth driven by COVID-19 and routine testing HY 2021 HY 2020 Change in % CHFm CHFm CHF CER Diagnostics Division 9,042 6,079 49 51 Core Lab 3,726 2,821 32 34 Molecular Lab 2,216 1,558 42 45 Point of Care 1,616 360 349 349 Diabetes Care 894 832 7 10 Pat
Slide 31: Diagnostics Division sales growth by quarter
Diagnostics Division sales growth by quarter Accelerated growth of routine testing in H1 55% 48% Diagnostics Division sales growth 28% Routine sales growth 1 31% 18% 17% 5% 2% 1% -2% -5% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 -17% COVID-19 Q1: 0.1bn Q2: 0.6bn Q3: 0.6bn Q4: 1.1bn Q1: 1.2bn Q2: 1.3bn sal
Slide 32: HY 2021: Diagnostics Division regional sales
HY 2021: Diagnostics Division regional sales Very strong growth in all regions North America +25% EMEA1 ~23% of divisional sales +70% ~46% of divisional sales Asia Pacific Latin America +44% +77% ~25% of divisional sales ~6% of divisional sales All growth rates at Constant Exchange Rates (CER); 1 Eu
Slide 33: HY 2021: Diagnostics Division highlights
HY 2021: Diagnostics Division highlights Very strong growth across all businesses YoY CER growth Core Lab +34% • Immunodiagnostics (+40%) • Clinical Chemistry (+25%) Molecular • Virology (+60%) +45% • LightMix Systems (+44%) Lab1 • POC Molecular (+318%) Point of • POC Immunodiagnostics (>2,000%) +34
Slide 34: HY 2021: Diagnostics Division Core operating profit more than doubled
HY 2021: Diagnostics Division Core operating profit more than doubled HY 2021 2021 vs. 2020 CHFm % sales CER growth Sales 9,042 100 51% Royalties & other op. inc. 48 0.5 79% Cost of sales -4,355 -48.2 51% M&D -1,330 -14.7 8% R&D -807 -8.9 16% G&A -274 -3.0 25% Core operating profit 2,324 25.7 137% +
Slide 35: SARS-CoV-2 Diagnostics portfolio
SARS-CoV-2 Diagnostics portfolio1 Comprehensive portfolio of tests and digital solutions Clinical Labs Near Patient • cobas® SARS-CoV-2 Launched • cobas® SARS-CoV-2 Variant set 1 Launched 7 • cobas® SARS-CoV-2 & Influenza A/B Launched Molecular • cobas® SARS-CoV-2 Launched • cobas® SARS-CoV-2 & Infl
Slide 36: Close of GenMark acquisition
Close of GenMark acquisition on April 24th Focus on global expansion of high-medical value syndromic panels ePlex System (CE1 & 510k2) • Complementing our portfolio, offering the broadest coverage of infectious organisms and resistance genes • On market: − 2 ePlex Respiratory Pathogen Panels (20 vir
Slide 37: Claim extensions for cardiac NT-proBNP and Troponin T
Claim extensions for cardiac NT-proBNP and Troponin T Preventing diseases in 5 new clinical settings On-Market New Diagnosis Screening Clinical “Rule out” high CV Chest pain Perioperative risk Asymptomatic population at risk Troponin T- setting risk in ACS high sensitive Patient 100 million1 200 mil
Slide 38: Elecsys Anti-p53 immunoassay received CE mark
Elecsys® Anti-p53 immunoassay received CE mark Aids in earlier diagnosis of esophageal, colorectal & breast cancers Elecsys® Sandwich principle • Over 2 million deaths in 2020 related to these three cancers1 Phase 1 Ru • Between 20-50% of patients with mutated p53 will produce 9 min anti-p53 autoant
Slide 39: MMR RxDx Panel received FDA approval
MMR RxDx Panel received FDA approval VENTANA preferred partner for companion diagnostics Damaged DNA MSH2/MSH6: Loss of expression of • >380,000 new cases of endometrial cancer (EC) each year1 Mismatch recognition MSH2 MSH6 MSH2 or MSH6 indicates MMR deficiency • First MMR IHC-based companion diagno
Slide 40: Roche's first step into Automated Insulin Delivery
Roche’s first step into Automated Insulin Delivery (AID) Hybrid-closed loop mode for Accu-Chek Insight insulin pump users Accu-Chek Insight CGM Automated delivery of Continuous measurement insulin based on algorithm informing algorithm Self-learning AID Algorithm Determines the correct dose of insul
Slide 41: Key launches 2021
Key launches 2021 Area Product Description Market cobas® pure integrated solutions Low-to-medium volume SWA CE Core Lab cobas® pro integrated solutions New high throughput configurations of the cobas pro instrument US & CE Point of Care cobas® pulse Successor of Accu-Chek® Inform II CE Instruments c
Slide 42: Finance
Finance Alan Hippe Chief Financial Officer
Slide 43: HY 2021 results, Focus on Cash, Outlook
HY 2021 results Focus on Cash Outlook 43
Slide 44: HY 2021: Highlights
HY 2021: Highlights Business • Sales growth of +8% and Core operating profit up +4% • Core EPS growth +6% Cash flow • Operating Free Cash Flow of CHF 8.1bn, +71% higher due to lower payments related to trade and other accounts payable and lower investment in alliance arrangements and in-licensing •
Slide 45: HY 2021: Group performance
HY 2021: Group performance Sales growth of +8% and Core EPS growth of +6% HY 2021 HY 2020 Change in % CHFm CHFm CHF CER Sales 30,713 29,281 5 8 Core operating profit 11,652 11,766 -1 4 as % of sales 37.9 40.2 Core net income 9,527 9,443 1 6 as % of sales 31.0 32.2 Core EPS (CHF) 10.56 10.44 1 6 IFRS
Slide 46: HY 2021: Core EPS development
HY 2021: Core EPS development Growth driven by gains on product disposals & equity securities +5.7% HY 2020 HY 2021 All at CER (Constant Exchange Rates); * Core Operating profit excluding impacts from changes in gains on product disposals; ** Other (net) includes effects from changes in: financial i
Slide 47: HY 2021: Group operating performance
HY 2021: Group operating performance Core operating profit growth of +4% HY 2021 2021 vs. 2020 CHFm abs. CER CER growth Sales 30,713 +2,389 8% Royalties & other op. inc. 1,420 +374 35% Cost of sales -8,237 -1,294 19% M&D -4,292 +91 -2% R&D -6,690 -1,077 19% G&A -1,262 -58 5% Core operating profit 11
Slide 48: HY 2021: Royalties and other operating income
HY 2021: Royalties and other operating income Increase driven by higher income from disposal of products CHFm +354 +50 -58 -23 1,420 1,097 Royalties and other operating income increased by +35% at CER Royalty income Out-licensing Other operating Income from HY 2020 income income disp. of products HY
Slide 49: HY 2021: Core operating profit and margin
HY 2021: Core operating profit and margin 47.5% 47.2% 44.1% % of sales 40.6% 40.2% 37.9% -2.7%p¹ -1.7%p¹ 25.7% +4%¹ CHFm 17.0% 16.8% 12,363 +9.3%p¹ 11,766 11,652 11,500 -8%¹ 10,961 9,562 +137%¹ 2,324 1,064 1,022 2019 2020 2021 Roche Group Pharma Division Diagnostics Division 1 At CER=Constant Exchan
Slide 50: HY 2021: Core net financial result
HY 2021: Core net financial result Improvement driven by higher gains on equity securities & lower interest expenses CHFm • Net financial result improved by +57% at CER • Interest expenses1 decreased by +21% at CER -564 -186 +25 +57 -451 +31 -12 +164 HY Equity Net interest FX G/L Interest Other HY 2
Slide 51: HY 2021: Group Core tax rate
HY 2021: Group Core tax rate Lower effect from the resolution of tax disputes in 2021 (-1%p) compared to 2020 (-2%p) Figures in % +0.4%p 16.5 16.9 HY 2020 Increase in HY 2021 as reported Core tax rate as reported 51
Slide 52: HY 2021: Non-core and IFRS income
HY 2021: Non-core and IFRS income Non-core operating expenses above PY driven by Accutane provision release in 2020 and higher Global restructuring plans HY 2020 HY 2021 Change in % CHFm CHFm CHFm CHF CER Core operating profit 11,766 11,652 -114 -1 +4 Global restructuring plans -253 -511 -258 Amorti
Slide 53: HY 2021 results, Focus on Cash, Outlook
HY 2021 results Focus on Cash Outlook 53
Slide 54: HY 2021: Strong operating free cash flow and margin
HY 2021: Strong operating free cash flow and margin 33.9% 33.6% % of sales 24.6% 26.4% 23.5% 17.2% +10.6%p¹ +9.8%p¹ 13.0% +71%¹ -0.7% +41%¹ -6.1% +14.2%p¹ CHFm 8,117 8,191 7,508 7,282 5,454 5,036 n/a¹ 1,178 2019 2020 2021 -380 -44 Roche Group Pharma Division Diagnostics Division 1 At CER=Constant Ex
Slide 55: HY 2021: Group Operating Free Cash Flow
HY 2021: Group Operating Free Cash Flow Higher than PY (+71%) driven by NWC movement & lower investments in Intangible Assets CHFm +1,180 -369 -198 +2,056 +412 8,117 5,036 OFCF higher by +71%/+3,450m at CER HY 2020 OP, net of cash NWC Investments Investments Foreign HY 2021 adjustments movement in P
Slide 56: HY 2021: Group net debt up vs. YE 2020
HY 2021: Group net debt up vs. YE 2020 Driven by dividends paid Free Cash Flow CHF 6.0bn CHFbn vs. 3.3bn in 2020 -2.1 +8.1 Taxes -2.2 Treasury +0.1 -11.1 -1.9 Dividends paid -8.0 Trans. own eq. instr. -0.6 -7.0 M&A & All. trans. -1.9 Curr. Transl. & Other -0.6 Net debt Operating Non-Operating Divide
Slide 57: Balance sheet 30 June 2021
Balance sheet 30 June 2021 Equity ratio at 47% (31 Dec 2020: 46%; 30 June 2020: 43%) % change in CER % change in CER CHFbn vs 31 Dec 2020 vs 31 Dec 2020 86.1 87.9 0% 86.1 87.9 0% Cash and 8.0 -35% 12.3 marketable 14% 9% 25.2 25.4 -4% securities 23.3 Current 29% 29% 20.6 +11% liabilities Other 26% cu
Slide 58: HY 2021 results, Focus on Cash, Outlook
HY 2021 results Focus on Cash Outlook 58
Slide 59: Currency impact expected to reduce as 2021 progresses
Currency impact expected to reduce as 2021 progresses CHF / USD -7% -6% -5% -4% 0.97 0.97 0.95 0.94 Average YTD 2020 Assuming the 30 June 2021 exchange rates remain stable until end of 2021, 0.91 0.91 0.91 0.90 2021 impact 1 is expected to be (%p): Assumed average YTD 2021 0.89 0.90 0.93 0.92 0.90 0
Slide 60: 2021 outlook confirmed
2021 outlook confirmed Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID
Slide 61: Changes to the development pipeline
Changes to the development pipeline Q2 2021 update New to phase I New to phase II New to phase III New to registration 2 NMEs: 3 NMEs: 1 NME: 1 NME: RG6189 FAP-CD40 – solid tumors RG6139 PD1xLAG3 – solid tumors RG6422 AT-527 – SARS-CoV-2 RG7716 faricimab – DME RG6338 NME – metabolic diseases RG7769
Slide 62: Roche Group development pipeline
Roche Group development pipeline Phase I (39 NMEs + 12 AIs) Phase II (25 NMEs + 13 AIs) RG6007 HLA-A2-WT1 x CD3 AML CHU FIXa x FX haemophilia tiragolumab + T NSCLC RG6026 glofitamab monotherapy and combos heme tumors CHU glypican-3 x CD3 solid tumors tiragolumab + T + chemo 1L non-squamous NSCLC RG6
Slide 63: Roche Group development pipeline
Roche Group development pipeline Phase III (15 NMEs + 39 AIs) Registration (3 NMEs + 4 AIs) Kadcyla + T 2L+ HER-2+ PD-L1+ mBC Venclexta r/r MM t(11:14) Gavreto (pralsetinib) 1 RET+ NSCLC RG3502 RG7601 RG6396 Kadcyla + T HER-2+ eBC high-risk Venclexta + azacitidine 1L MDS Gavreto (pralsetinib) 2 RET+
Slide 64: NME submissions and their additional indications
NME submissions and their additional indications Projects in phase II and III glofitamab + chemo autogene cevumeran semorinemab RG6026 RG6180 RG6100 2L DLBCL 1L melanoma Alzheimer’s rhPTX-2 brain shuttle glofitamab tiragolumab + T RG6026 RG6058 RG6354 (PRM-151) RG6102 gantenerumab 3L+ DLBCL 1L PD-L1
Slide 65: AI submissions for existing products
AI submissions for existing products Projects in phase II and III New Molecular Entity (NME) Immunology Neuroscience Xofluza Additional Indication (AI) Infectious Diseases Ophthalmology RG6152 direct transmission Oncology / Hematology Metabolism Other Xofluza RG6152 influenza, pediatric (0-1 year) X
Slide 66: Major pending approvals 2021
Major pending approvals 2021 US EU China Japan-Chugai PDS with ranibizumab Gavreto (pralsetinib) Tecentriq faricimab RG6321 wAMD RG6396 RET+ NSCLC RG7446 NSCLC adj RG7716 DME Filed April 2021 Filed May 2020 Filed June 2021 Filed June 2021 faricimab Tecentriq + nab-paclitaxel faricimab RG7716 DME RG7
Slide 67: Major granted approvals 2021
Major granted approvals 2021 US EU China Japan-Chugai Alecensa (BFAST) Xofluza Xofluza Polivy RG7853 1L NSCLC ALK+ RG6152 influenza, otherwise healthy RG6152 influenza, otherwise healthy RG7596 r/r DLBCL Jan 2021 Jan 2021 April 2021 March 2021 Actemra Xofluza Xofluza Evrysdi RG1569 SSc-ILD RG6152 in
Slide 68: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 68
Slide 69: Hemophilia: Hemlibra
Hemlibra Factor VIII mimetic for treatment of hemophilia A Hemophilia A patients Hemophilia A patients with and without inhibitors to Factor VIII, Indication without inhibitors to factor VIII dosing every 4 weeks Phase III Phase III Phase/study HAVEN 3 HAVEN 4 # of patients N=135 N=46 Patients on FV
Slide 70: Hemophilia: Hemlibra
Hemlibra Factor VIII mimetic for treatment of hemophilia A Hemophilia A mild to moderate patients without inhibitors to Factor Indication Hemophilia A patients with and without inhibitors to Factor VIII VIII Phase III Phase III Phase/study HAVEN 5 HAVEN 6 # of patients N=85 N=70 Patients with Hemoph
Slide 71: Oncology: Alecensa
Alecensa New CNS-active inhibitor of anaplastic lymphoma kinase Treatment-naïve Indication Adjuvant ALK+ NSCLC ALK+ advanced NSCLC Phase III Phase III Phase/study ALEX ALINA # of patients N=286 N=255 ARM A: Alecensa 600mg BID ARM A: Alecensa 600 mg BID Design Oncology ARM B: Crizotinib 250mg B
Slide 72: Oncology: Kadcyla
Kadcyla First ADC for HER2-positive breast cancer HER2-positive early breast cancer HER2-positive early breast cancer Indication 2L+ HER-2 positive PD-L1 positive mBC high-risk patients high-risk patients Phase III Phase III Phase III Phase/study KATHERINE KATE 3 ASTEFANIA # of patients N=1,484 N=35
Slide 73: Oncology: Perjeta
Perjeta First-in-class HER2 dimerization inhibitor Indication Adjuvant HER2-positive breast cancer HER2-positive early breast cancer subcutaneous co-formulation Phase III Phase III Phase II Phase/study APHINITY FeDeriCa PHranceSCa # of patients N=4,803 N=500 N=160 ARM A: Perjeta (840mg loading, 42
Slide 74: Oncology: Tecentriq lung cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer 1L non-squamous and squamous NSCLC Indication 1L non-squamous NSCLC 1L extensive-stage SCLC PD-L1-selected patients Phase III Phase III Phase/study Phase Ib IMpower132 IMpower110 # of patients N=568 N=570 N=62 ARM A: Tecentriq plus carboplati
Slide 75: Oncology: Tecentriq lung cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer 2L NSCLC previously treated with an Indication Adjuvant NSCLC Neoadjuvant NSCLC immune checkpoint inhibitor Phase III Phase III Phase III Phase/study IMpower010 IMpower030 CONTACT-01 # of patients N=1,280 N=450 N=350 Following adjuvant cisplati
Slide 76: Oncology: Tecentriq lung cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer Indication 1L NSCLC Stage IV NSCLC Phase II/III Phase Ib/III Phase/study B-FAST IMscin0011 # of patients N=660 N=375 Cohort A: ALK+ (Alecensa) Phase Ib Cohort B: RET+ (Alecensa) Dose finding, Tecentriq SC followed by Tecentriq IV Cohort
Slide 77: Oncology: Tecentriq SCCHN and melanoma
Tecentriq Anti-PD-L1 cancer immunotherapy – SCCHN and melanoma First-line BRAFv600 mutation-positive metastatic or unresectable Indication Adjuvant squamous cell carcinoma of the head and neck locally advanced melanoma Phase III Phase III Phase/study IMvoke010 IMspire150 TRILOGY1 # of patients N=400
Slide 78: Oncology: Tecentriq UC
Tecentriq Anti-PD-L1 cancer immunotherapy – UC High-risk non-muscle-invasive ctDNA+, high-risk muscle-invasive Indication 1L metastatic urothelial carcinoma bladder cancer bladder cancer Phase III Phase III Phase III Phase/study IMvigor130 ALBAN IMvigor011 # of patients N=1,200 N=516 N=495 ARM A:
Slide 79: Oncology: Tecentriq renal cell cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – renal cell cancer Advanced renal cell carcinoma after immune checkpoint inhibitor Indication Adjuvant renal cell carcinoma treatment Phase III Phase III Phase/study IMmotion010 Contact-031 # of patients N=778 N=500 ARM A: Tecentriq monotherapy ARM A: T
Slide 80: Oncology: Tecentriq HCC
Tecentriq Anti-PD-L1 cancer immunotherapy – HCC Indication 1L hepatocellular carcinoma Adjuvant hepatocellular carcinoma Phase III Phase III Phase/study IMbrave150 IMbrave050 # of patients N=501 N=662 ARM A: Tecentriq plus Avastin ARM A: Tecentriq plus Avastin ARM B: Sorafenib ARM B: Active
Slide 81: Oncology: Tecentriq breast cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – breast cancer Previously untreated metastatic Indication triple negative breast cancer Phase III Phase III Phase/study IMpassion130 IMpassion132 # of patients N=900 N=572 ARM A: Tecentriq plus nab-paclitaxel ARM A: Tecentriq plus capecitabine or carbo/
Slide 82: Oncology: Tecentriq breast cancer
Tecentriq Anti-PD-L1 cancer immunotherapy – breast cancer Indication Neoadjuvant triple negative breast cancer Adjuvant triple negative breast cancer Phase III Phase III Phase/study IMpassion031 IMpassion030 # of patients N=324 N=2,300 ARM A: Tecentriq plus nab-paclitaxel ARM A: Tecentriq + pacl
Slide 83: Oncology: Venclexta CLL
Venclexta Novel small molecule Bcl-2 selective inhibitor – CLL Untreated CLL patients with Indication Relapsed or refractory CLL Untreated fit CLL patients coexisting medical conditions Phase III Phase III Phase III Phase/study CLL14 MURANO CristaLLo # of patients N=432 N=391 N=165 ARM A: Venclext
Slide 84: Oncology: Venclexta MM
Venclexta Novel small molecule Bcl-2 selective inhibitor – MM Indication Relapsed or refractory multiple myeloma Phase III Phase/study Phase I Phase Ib/II CANOVA # of patients N=166 N=120 N=244 Dose escalation cohort: Venclexta plus carfilzomib plus dexamethasone Venclexta plus dexamethazone v
Slide 85: Oncology: Venclexta AML
Venclexta Novel small molecule Bcl-2 selective inhibitor – AML Indication Relapsed or refractory AML Relapsed or refractory hematological malignancies Phase/study Phase I Phase I # of patients N=52 N=86 Venclexta in combination with gilteritinib Venclexta plus AMG176 dose escalation Dose expan
Slide 86: Oncology: Venclexta MDS
Venclexta Novel small molecule Bcl-2 selective inhibitor – MDS Relapsed or refractory myelodysplastic Newly diagnosed higher-risk Indication Treatment-naive myelodysplastic syndromes syndromes myelodysplatic syndrome Phase III Phase/study Phase Ib Phase Ib VERONA # of patients N=70 N=137 N=500 Cohor
Slide 87: Oncology: Polivy
Polivy (polatuzumab vedotin) ADC targeting CD79b to treat B cell malignancies Relapsed or refractory Indication 1L DLBCL FL and DLBCL Phase III Phase/study Phase Ib/II POLARIX # of patients N=329 N=875 PIb: Dose escalation ARM A: Polatuzumab vedotin plus R-CHP PhII: Polatuzumab vedotin plus BR
Slide 88: Oncology: Rozlytrek
Rozlytrek (entrectinib) CNS-active and selective inhibitor of NTRK/ROS1 Locally Advanced or Metastatic tumors with Locally Advanced or Metastatic tumors with Pediatric tumors with NTRK 1/2/3, ROS-1 Indication ROS1 gene rearrangement NTRK1/2/3 gene rearrangement or ALK rearrangement Phase II Phase II
Slide 89: Oncology: Gavreto
Gavreto (pralsetinib, RG6396) Highly selective RET inhibitor RET+ NSCLC, thyroid cancer and Indication 1L RET fusion-positive, metastatic NSCLC other advanced solid tumors Phase I/II Phase III Phase/study ARROW AcceleRET Lung # of patients N=647 N=250 Part 1: Gavreto 30-600mg dose-escalation Arm
Slide 90: Neuroscience: Ocrevus
Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells Primary-progressive Indication Relapsing multiple sclerosis (RMS) multiple sclerosis (PPMS) Phase III Phase III Phase III Phase/study OPERA I OPERA II ORATORIO # of patients N=821 N=835 N=732 96-week treatment period: 96
Slide 91: Neuroscience: Ocrevus
Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells Relapsing and primary progressive multiple sclerosis (RMS & Indication Primary progressive multiple sclerosis (PPMS) PPMS) Phase IIIb Phase IIIb Phase/study ENSEMBLE PLUS ORATORIO-HAND # of patients N=1225 N ~ 1000 • Sub
Slide 92: Neuroscience: Ocrevus
Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) Phase IIIb Phase IIIb Phase/study GAVOTTE MUSETTE # of patients N ~ 699 N ~ 786 120-week treatment period: 120-week treatment pe
Slide 93: Neuroscience: Evrysdi
Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Spinal muscular atrophy Phase II/III Phase II/III Phase II Phase/study FIREFISH SUNFISH JEWELFISH # of patients N=21 (Part 1), 41 (Part 2) N=51 (Part 1), 180 (Part 2) N=174 Open-label study in infants with type 1 spinal muscular Rand
Slide 94: Neuroscience: Evrysdi
Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Spinal muscular atrophy Phase II Phase/study RAINBOWFISH # of patients N=25 Open-label, single-arm, multicenter study in infants aged from birth to 6 weeks who have been genetically diagnosed with SMA but are not yet presenting with
Slide 95: Neuroscience: Enspryng
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Neuromyelitis optica spectrum disorder (NMOSD) Phase III Phase III Phase/study Sakura Star Sakura Sky # of patients N=95 N=70 (adults); N=6 (adolescents) Satralizumab as monotherapy: Add-on therapy of
Slide 96: Neuroscience: Enspryng
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Generalised Myasthenia Gravis Phase III Phase/study Luminesce # of patients N=240 • Group A: Satralizumab plus SoC • Group B: Placebo plus SoC Design Neuroscience Mean change from baseline in total M
Slide 97: Immunology: Gazyva
Gazyva (obinutuzumab) Immunology development program Indication Lupus nephritis Membranous nephropathy Phase II Phase III Phase III Phase/study NOBILITY REGENCY MAJESTY # of patients N=126 N=252 N=140 ARM A: Obinutuzumab 1000mg IV plus ARM A: Obinutuzumab 1000 mg IV (six doses ARM A: Obinutuzu
Slide 98: Immunology: Actemra/RoActemra
Actemra/RoActemra (RG-1569) Interleukin 6 receptor inhibitor Indication Adult hospitalised with severe COVID-19 pneumonia Phase III Phase III Phase/study COVACTA1 REMDACTA2 # of patients N=450 N=650 Arm A: tocilizumab plus standard of care Arm A: remdesivir plus tocilizumab Arm B: placebo plus
Slide 99: Immunology: Actemra/RoActemra
Actemra/RoActemra (RG-1569) Interleukin 6 receptor inhibitor Indication Adult hospitalised with severe COVID-19 pneumonia Phase II Phase III Phase/study MARIPOSA EMPACTA # of patients N=100 N=379 Arm A: 8 mg/kg tocilizumab plus standard of care Conducted in sites known to provide critical care to
Slide 100: Immunology: Xolair
Xolair Humanized mAb that selectively binds to IgE Indication Food allergy Phase III Phase/study OUtMATCH1 # of patients N=225 • Xolair by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks Immunology Design Primary endpoint • Number of participants who successfully cons
Slide 101: Infectious Diseases: Xofluza
Xofluza (baloxavir marboxil, RG6152, S-033188 ) Small molecule, novel CAP-dependent endonuclease inhibitor Indication Influenza Phase III Phase III Phase/study miniSTONE 1 (0-1 year old) miniSTONE 2 (1-12 years old ) # of patients N=30 N=176 • Xofluza on Day 1 (based on body weight and age) in healt
Slide 102: Infectious Diseases: Xofluza
Xofluza (baloxavir marboxil, RG6152, S-033188) Small molecule, novel CAP-dependent endonuclease inhibitor Indication Influenza Phase III Phase IIIb Phase/study BLOCKSTONE CENTERSTONE N=752 N=3,160 # of patients Post exposure prophylaxis to prevent disease onset in household Reduction of direct t
Slide 103: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 103
Slide 104: Oncology: Ipatasertib
Ipatasertib (RG7440, GDC-0068) Highly selective small molecule inhibitor of Akt Prostate cancer previously treated with Indication 1L castration-resistant prostate cancer Advanced prostate cancer and solid tumors androgen receptor-targeted therapy Phase III Phase/study Phase Ib Phase Ib IPATential15
Slide 105: Oncology: Ipatasertib
Ipatasertib (RG7440, GDC-0068) Highly selective small molecule inhibitor of Akt Indication 1L HR+ mBC Phase Ib/III Phase/study IPATunity150 # of patients N=370 ARM A: Ipatasertib plus fulvestrant and palbociclib ARM B: Placebo plus fulvestrant and palbociclib Design Oncology Primary endpoint P
Slide 106: Oncology: Tiragolumab
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication 1L NSCLC PD-L1 TPS>50% 1L ES-SCLC Stage III unresectable 1L NSCLC Phase III Phase III Phase III Phase/study SKYSCRAPER-01 SKYSCRAPER-02 SKYSCRAPER-03 # of patients N=500-560 N=4
Slide 107: Oncology: Tiragolumab
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Metastatic and/or recurrent PD-L1+ Indication Neoadjuvant and adjuvant NSCLC 1L non-squamous NSCLC cervical cancer Phase II Phase II Phase II Phase/study SKYSCRAPER-04 SKYSCRAPER-05 SKYSCR
Slide 108: Oncology: Tiragolumab
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT 1L recurrent/metastatic PD-L1 positive Indication Locally advanced esophageal cancer 1L esophageal cancer squamous cell head and neck carcinoma Phase III Phase III Phase II Phase/study SKY
Slide 109: Oncology: Tiragolumab
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT R/R Multiple Myeloma (MM) or R/R B-cell Indication Solid tumors NSCLC NHL Phase II Phase/study Phase I Phase l CITYSCAPE # of patients N=540 N=135 N=52 Phase Ia: Dose escalation and expa
Slide 110: Oncology: Glofitamab
Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory Non-Hodgkin’s lymphoma Non-Hodgkin’s lymphoma Phase/study Phase I Phase Ib Phase Ib Part I: 15-60 # of patients N=700 N=140 Part II: ~66-104 Cohort 1: Single-agent
Slide 111: Oncology: Glofitamab
Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Relapsed/refractory DLBCL and High-Grade Large B-Cell Indication 2L+ SCT-ineligible DLBCL Lymphoma Phase III Phase/study Phase Ib STARGLO # of patients N=20 N=270 Glofitamab plus gemcitabine and o
Slide 112: Oncology: Mosunetuzumab
Mosunetuzumab (CD20/CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 3L+ FL, 3L+ DLBCL & other R/R NHL 1L DLBCL R/R DLBCL Phase/study Phase I Phase Ib/II Phase Ib # of patients N=746 N=160 N=262 Dose escalation study of mosunetuzumab as Mosunetuzuma
Slide 113: Oncology: Mosunetuzumab
Mosunetuzumab (CD20/CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 1L DLBCL & 2L DLBCL following 1L induction R/R 2L+ FL Phase/study Phase I Phase Ib # of patients N=92 + 80 (cohort C) N=27 Cohort A: Mosunetuzumab monotherapy (after a response to pr
Slide 114: Oncology: Inavolisib
Inavolisib (RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor PIK3CA mutant solid tumors and metastatic Indication PIK3CA-mutant HR+ mBC ER+ HER2-neg breast cancer Phase III Phase/study Phase I INAVO120 # of patients N=400 N=156 Arm A: GDC-0077 plus palbociclib plus fulve
Slide 115: Oncology: Giredestrant
Giredestrant (SERD (3),RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator ER+ HER2-neg Stage I-III operable breast Indication ER+ HER2-neg metastatic breast cancer Neoadjuvant ER+ breast cancer cancer Phase II Phase/study Phase I Phase I coopERA Breast Cancer # of patients N=2
Slide 116: Oncology: Giredestrant
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator 2L/3L ER+/HER2-negative Indication 1L ER+ metastatic breast cancer Adjuvant ER+ breast cancer metastatic breast cancer Phase II Phase III Phase III Phase/study acelERA Breast Cancer persevERA Breast Can
Slide 117: Oncology: rhPTX-2
rhPTX-2 (RG6354) Recombinant human innate immunity protein pentraxin-2 Indication Myelofibrosis Phase/study Phase II # of patients N=125 • Multiple dose study of rhPTX-2 Oncology Design • Bone marrow response rate Primary endpoint Study completed Q1 2021 Status CT Identifier NCT01981850 117
Slide 118: Immunology: rhPTX-2
rhPTX-2 (RG6354) Recombinant human innate immunity protein pentraxin-2 Indication Idiopathic pulmonary fibrosis (IPF) Phase III Phase/study Phase II STARSCAPE # of patients N=117 N=658 Randomized, double-blind, placebo-controlled trial: 4-week screening Randomized, double-blind, placebo-controll
Slide 119: Immunology: Fenebrutinib
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase inhibitor Indication (BTKi) Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) Phase III Phase III Phase III Phase/study FENtrepid FENhance 1 FENhance 2 # of patients N=
Slide 120: Immunology: Etrolizumab
Etrolizumab (RG7413) Humanized mAb against beta 7 integrin Indication Moderately to severely active Crohn’s disease Moderately to severely active Crohn’s disease Phase III Phase III Phase/study BERGAMOT JUNIPER Induction and maintenance study Open label extension study for BERGAMOT # of patients N=1
Slide 121: Immunology: Crovalimab
Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Paroxysmal nocturnal hemoglobinuria (PNH) Phase I/II Phase/study COMPOSER # of patients N=59 Healthy volunteers and treatment naïve and pretreated patients with PNH: Part 1: single ascending dose study in h
Slide 122: Immunology: Crovalimab
Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Sickle Cell Disease (SCD) Indication Atypical Hemolytic Uremic Syndrome (aHUS) Acute treatment Phase III Phase I Phase/study COMMUTE-a CROSSWALK-a # of patients N=90 N=30 Single-arm study of aHUS patients Cohort 1: Cr
Slide 123: Immunology: Crovalimab
Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Indication (PNH) patients switching from a C5 (PNH) (PNH) inhibitor C5 inhibitor naive patients C5 inhibitor na
Slide 124: Neuroscience: Crenezumab
Crenezumab (RG7412) Humanized mAb targeting all forms of A Indication Alzheimer’s Prevention Initiative (API) Colombia Phase II Phase/study Cognition study # of patients N=252 ARM A: PSEN1 E280A mutation carriers receive crenezumab SC ARM B: PSEN1 E280A mutation carriers receive placebo Design
Slide 125: Neuroscience: Gantenerumab
Gantenerumab (RG1450) Fully human mAb binding aggregated forms of A Indication Prodromal to mild Alzheimer’s disease Phase III Phase III Phase/study GRADUATE 1 GRADUATE 2 # of patients N=1,016 N=1,016 104-week subcutaneous treatment period: 104-week subcutaneous treatment period: ARM A: Ganteneru
Slide 126: Neuroscience: Gantenerumab
Gantenerumab (RG1450) Fully human mAb binding aggregated forms of A Indication Prodromal Alzheimer’s disease Mild Alzheimer’s disease Phase II/III Phase III Phase/study SCarlet RoAD Marguerite RoAD # of patients N=799 N=389 104-week subcutaneous treatment period: 104-week subcutaneous treatment per
Slide 127: Neuroscience: Tominersen
Tominersen (RG6042, HTT ASO ) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington’s disease Phase II Phase/study Phase I/IIa OLE # of patients N=46 N=46 Multiple ascending doses of RG6042 administered intrathecally to adult Patients from phase I are enrolled into OLE p
Slide 128: Neuroscience: Tominersen
Tominersen (RG6042, HTT ASO ) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington’s disease Phase III Phase III Phase/study Generation HD1 GEN-EXTEND # of patients N=791 N=1,050 ARM A: RG6042 120mg bimonthly Open-Label Extension study in patients participating in prior R
Slide 129: Ophthalmology: Faricimab
Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Center-involving diabetic macular edema Indication Neovascular age related macular degeneration (nAMD) (CI-DME) Phase II Phase II Phase II Phase/study AVENUE STAIRWAY BOULEVARD # of patients N=271 N=75 N=210 ARM A: SoC
Slide 130: Ophthalmology: Faricimab
Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Indication Center-involving diabetic macular edema (CI-DME) Phase III Phase III Phase/study YOSEMITE RHINE # of patients N=940 N=951 ARM A: Faricimab q8w ARM A: Faricimab q8w ARM B: Faricimab PTI up to q16w ARM B:
Slide 131: Ophthalmology: Faricimab
Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Indication Neovascular age related macular degeneration (nAMD) Phase III Phase III Phase/study TENAYA LUCERNE # of patients N=671 N=658 ARM A: Faricimab 6.0mg Q16 flex after 4 initiating doses (IDs) ARM A: Faricimab 6
Slide 132: Ophthalmology: Faricimab
Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Indication Macular edema secondary to branch retinal vein occlusion Macular edema secondary to central retinal vein occlusion Phase III Phase III Phase/study BALATON COMINO # of patients N=570 N=750 ARM A: Faricimab, q4
Slide 133: Ophthalmology: Port Delivery System with ranibizumab
Port Delivery System with ranibizumab First eye implant to achieve sustained delivery of a biologic medicine Indication wAMD Phase III Phase II+III extension Phase IIIb Phase/study Archway Portal Velodrome # of patients N=418 N=500 N=442 ARM A: PDS with ranibizumab every 24 weeks Patients from L
Slide 134: Ophthalmology: Port Delivery System with ranibizumab
Port Delivery System with ranibizumab First eye implant to achieve sustained delivery of a biologic medicine Diabetic retinopathy without Indication DME center-involved diabetic macular edema Phase III Phase III Phase/study Pagoda Pavilion # of patients N=545 N=160 ARM A: PDS with ranibizumab ever
Slide 135: Infectious Diseases: AT-527
AT-527 (RG6422) Viral RNA polymerase inhibitor Indication Non-hospitalised adult patients with mild or moderate COVID-19 Adult patients SARS-COV-2 positive in an outpatient setting Phase II Phase III Phase/study MOONSONG MORNINGSKY # of patients N=220 N=1,386 ARM A: AT-527 Arm A: AT-527 550mg BI
Slide 136: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 136
Slide 137: pRED oncology development programs -1
pRED oncology development programs -1 Molecule Indication Phase # of patients Status CT Identifier Oncology TYRP1 x CD3 (RG6232) Melanoma I 210 FPI Q4 2020 NCT04551352 FPI Q2 2018 Solid tumors I ~150 Data presented at ESMO 2020 FAP-4-1BBL (RG7827) Recruitment completed Q2 2021 FPI July 2021 3L+ MSS
Slide 138: pRED oncology development programs -2
pRED oncology development programs -2 Molecule Indication Phase # of patients Status CT Identifier Oncology Solid tumors I 110 FPI Q4 2019 NCT04158583 CD25 (RG6292) Advanced and metastatic solid I 160 FPI Jan 2021 NCT04642365 tumors TLR7 agonist (4) (RG6115) Hepatocellular carcinoma I 100 FPI July 2
Slide 139: pRED neuroscience development programs
pRED neuroscience development programs Molecule Indication Phase # of patients Status CT Identifier Neuroscience Brain Shuttle gantenerumab Alzheimer's disease II ~120 FPI Q1 2021 NCT04023994 (RG6102) II 36 FPI Q4 2018; Recruitment completed Q3 2019 NCT03669640 ralmitaront II 247 FPI Q4 2019 Schizop
Slide 140: pRED immunology and ophthalmology development programs
pRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology Ulcerative Colitis Ib 65 FPI Q2 2019 NCT03943550 IgG-IL2 (RG7835) NCT04790916 Autoimmune diseases II 84 FPI Q2 2021 GOLDSTONE Ophthalmology NME (RG6179)1 DME I 50 FPI July 2
Slide 141: pRED infectious diseases development programs
pRED infectious diseases development programs Molecule Indication Phase # of patients Status CT Identifier Infectious Diseases FPI Q4 2016 TLR7 agonist (3) (RG7854) Chronic hepatitis B I 150 NCT02956850 Data presented at APASL 2019 FPI Q4 2016 Data presented at EASL 2018, 2019 & 2020 I/II 192 Part 1
Slide 142: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 142
Slide 143: gRED oncology development programs
gRED oncology development programs Molecule Indication Phase # of patients Status CT Identifier Oncology Metastatic solid tumors with KRAS KRAS G12C (RG6330) I 108 FPI Q3 2020 NCT04449874 G12C mutation cevostamab R/R multiple myeloma I 300 FPI Q3 2017 NCT03275103 (anti-FcRH5 x CD3; RG6160) Metastati
Slide 144: gRED immunology and ophthalmology development programs
gRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology Inflammatory diseases Ib 90 FPI Q2 2016 NCT02749630 efmarodocokin alfa Inflammatory bowel disease II 270 FPI Q4 2018 NCT03558152 (IL-22Fc, RG7880) aGVHD lb 24 FPI Q4 2020 NC
Slide 145: gRED neuroscience and metabolic diseases development programs
gRED neuroscience and metabolic diseases development programs Molecule Indication Phase # of patients Status CT Identifier Neuroscience FPI Q4 2017 Prodromal to mild NCT03289143 II 457 Primary endpoint not met Q3 2020 Alzheimer’s disease (TAURIEL) Semorinemab (RG6100)1 Data at CTAD 2020 FPI Q1 2019
Slide 146: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 146
Slide 147: Hemophilia A gene therapy
Hemophilia A Unique gene therapy platform SPK-8011 SPK-8016 Molecule (RG6357) (RG6358) Indication Hemophilia A Hemophilia A with inhibitors to Factor VIII Phase/study Phase I Phase I/II Phase I/II # of patients N=100 N=30 N=30 Long term follow up study of patients who Gene transfer, dose-finding
Slide 148: Ophthalmology: Choroideremia
Choroideremia Unique gene therapy platform SPK-7001 Molecule (RG6367) Indication Choroideremia Phase/study Phase I/II # of patients N=15 Safety study in subjects with CHM (choroideremia) gene mutations Ophthalmology Design Safety and tolerability Primary endpoint FPI Q1 2015 Status Recruitme
Slide 149: Metabolic diseases: Pompe disease
Pompe disease Unique gene therapy platform SPK-3006 Molecule (RG6359) Indication Pompe disease Phase I/II Phase/study RESOLUTE # of patients N=20 Metabolic diseases Gene transfer study for late-onset Pompe disease Design Safety Primary endpoint Status FPI Q4 2020 CT Identifier NCT04093349 149
Slide 150: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 150
Slide 151: HY 2021: Group operating performance
HY 2021: Group operating performance Core operating profit growth of +4% HY 2021 2021 vs. 2020 CHFm % sales CER growth Sales 30,713 100.0 8% Royalties & other op. inc. 1,420 4.6 35% Cost of sales -8,237 -26.8 19% M&D -4,292 -14.0 -2% R&D -6,690 -21.8 19% G&A -1,262 -4.1 5% Core operating profit 11,6
Slide 152: HY 2021: Group Sales
HY 2021: Group Sales CER sales up by +8%, driven by Diagnostics Division, partly offset by a decrease in the US; Fx impact of -3%p -8% +4% +2% 0% +8% +5% Pharma Division Dia Division -3% +51% +51% -957 +3,058 +2,389 1,432 -938 +175 +90 +4 11 United States Europe Intl. Chugai Dia Division Group Fx Gr
Slide 153: Balance sheet: Net debt, gross debt, and total assets
Balance sheet: Net debt, gross debt, and total assets 11% 10% Net debt / 8% total assets 3% 2% 86.1 87.9 80.2 83.1 80.4 Total assets (CHFbn) Gross debt (CHFbn) Net debt 19.6 14.4 15.0 14.2 15.0 (CHFbn) 8.4 8.8 7.0 2.5 1.9 30 Jun 2019 31 Dec 2019 30 Jun 2020 31 Dec 2020 30 Jun 2021 153
Slide 154: Geographical sales split by Divisions and Group
Geographical sales split by Divisions and Group* CHFm HY 2020 HY 2021 % change CER Pharmaceuticals Division 23,202 21,671 -3 United States 12,464 10,802 -8 Europe 4,190 4,485 +4 Japan 1,908 1,808 0 International 4,640 4,576 +2 Diagnostics Division 6,079 9,042 +51 United States 1,583 1,849 +24 Europe
Slide 155: Pharma Division sales HY 2021 Top 20 products
Pharma Division sales HY 2021 Top 20 products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 2,438 23 1,849 18 422 38 - - 167 60 Perjeta 1,968 5 703 -3 578 -1 132 -6 555 28 Avastin 1,645 -40 530 -47 257 -69 330 -4 528 -12 Actemra / RoActemra 1,642
Slide 156: Pharma Division sales HY 2021 New products
Pharma Division sales HY 2021 New products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Erivedge 127 -9 81 -13 30 -5 - - 16 12 Perjeta 1,968 5 703 -3 578 -1 132 -6 555 28 Kadcyla 959 19 401 6 336 27 60 56 162 31 Gazyva 324 8 153 13 106 2 31 -9 34 22 Esb
Slide 157: Pharma Division CER sales growth: Global top 20 products
Pharma Division CER sales growth1 in % Global top 20 products Q1/20 Q2/20 Q3/20 Q4/20 Q1/21 Q2/21 Ocrevus 38 12 37 10 16 31 Perjeta 22 12 17 20 2 7 Avastin -13 -24 -30 -35 -40 -40 Actemra / RoActemra 30 40 27 29 22 12 Tecentriq 99 54 49 35 26 31 Herceptin -24 -33 -38 -43 -35 -35 Hemlibra 146 59 57 4
Slide 158: Pharma Division CER sales growth: Top products by region
Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Ocrevus 32 5 9 28 56 20 37 40 - - - - 74 55 77 41 Perjeta 7 0 -2 -3 13 4 -3 2 -9 0 -11 -2 52 135 23 34 Avastin -37 -47 -48 -46 -33 -61 -68 -69 -25 -7 -8 0 -1
Slide 159: CER sales growth: Quarterly development
CER sales growth (%) Quarterly development 2020 vs. 2019 2021 vs. 2020 Q1 Q2 Q3 Q4 Q1 Q2 Pharmaceuticals Division 7 -6 -4 -7 -9 4 United States 3 -10 -5 -13 -14 0 Europe 14 -3 2 -8 -6 15 Japan 3 -7 -13 -5 -7 7 International 16 5 -2 11 0 4 Diagnostics Division 5 2 18 28 55 48 Roche Group 7 -4 1 1 3 1
Slide 160: Ocrevus
Ocrevus CHFbn Global sales CER growth Regional sales CER growth 3.0 +23% US +18% 2.5 2.0 1.5 Europe +38% 1.0 International +60% 0.5 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 2,438m • US: Moving into earlier lines displacing orals; COVID-19 impact as vaccination programs are on-going • EU: Upt
Slide 161: Perjeta
Perjeta Global sales CER growth Regional sales CER growth CHFbn 2.5 +5% US -3% 2.0 Europe -1% 1.5 1.0 Japan -6% International +28% 0.5 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,968m • US: Patients with residual disease being switched to Kadcyla; Cannibalization from Phesgo • EU: COVID-19 im
Slide 162: Avastin
Avastin Global sales CER growth Regional sales CER growth CHFbn 4.0 -40% US -47% Europe -69% 3.0 Japan -4% 2.0 1.0 International -12% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,645m • US: Decline due to biosimilars • EU: Decline due to biosimilars • Japan: Limited decline due to biosimilars
Slide 163: Actemra / RoActemra
Actemra / RoActemra Global sales CER growth Regional sales CER growth CHFbn 2.0 +17% US +6% 1.5 Europe +16% 1.0 Japan +6% 0.5 International +63% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,642m • US: Increased demand for SC formulation (home administration) and due to COVID-19 • EU: Market le
Slide 164: Tecentriq
Tecentriq Global sales CER growth Regional sales CER growth CHFbn 2.0 +29% US +16% Europe +17% 1.5 1.0 Japan +84% 0.5 International +68% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,599m • US: Growth driven by first-in-class launches in 1L HCC, 1L SCLC and 1L TNBC • EU: Growth driven by first-
Slide 165: Herceptin
Herceptin Global sales CER growth Regional sales CER growth CHFbn 4.0 -35% US -56% Europe -25% 3.0 Japan -40% 2.0 1.0 International -19% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,396m • US: Biosimilar erosion; Switching of patients with residual disease to Kadcyla; Cannibalization from Phes
Slide 166: Hemlibra
Hemlibra Global sales CER growth Regional sales CER growth CHFbn 1.5 +45% US +34% Europe +95% 1.0 Japan +16% 0.5 International +138% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,393m • US: Continued share gains in non-inhibitors; Some COVID-19 impact • EU: Growth driven by strong non-inhibitor
Slide 167: MabThera / Rituxan
MabThera / Rituxan CHFbn Global sales CER growth Regional sales CER growth 4.0 -41% US -46% 3.0 Europe -35% Japan -35% 2.0 International -27% 1.0 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 1,379m • US: Decline due to biosimlars • EU: Decline due to biosimlars • Japan: Decline due to biosimilar
Slide 168: Kadcyla
Kadcyla Global sales CER growth Regional sales CER growth CHFbn +19% US +6% 1.2 1.0 0.8 Europe +27% 0.6 0.4 Japan +56% 0.2 International +31% 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 959m • US: Uptake in adjuvant eBC in patients with residual disease after neoadjuvant treatment • EU: Strong
Slide 169: Xolair
Xolair Global sales CER growth Regional sales CER growth CHFbn -1% 1.0 0.8 US -1% 0.6 0.4 0.2 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 887m • Xolair remains market leader in a growing biologics asthma market; • Growth in chronic idiopathic urticaria (CIU) CER=Constant Exchange Rates 169
Slide 170: Lucentis
Lucentis Global sales CER growth Regional sales CER growth CHFbn 1.0 -3% 0.8 0.6 US -3% 0.4 0.2 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 665m • Volume growth off-set by price decline; First biosimilar expected in H2 • Overall market shares stable CER=Constant Exchange Rates 170
Slide 171: Alecensa
Alecensa Global sales CER growth Regional sales CER growth CHFbn Global sales CER+20% growth Regional sales US CER growth +6% CHFbn 0.30.6 -2% US -10% Europe +15% 0.3 Europe -2% 0.20.4 Japan +9% 0.2 Japan -32% 0.2 0.1 International +52% 0.1 International +34% 0.0 0.0 HY 18 HY 19 HY 20 HY 21 Q1 18 Q1
Slide 172: TNKase / Activase
TNKase / Activase Global sales CER growth Regional sales CER growth CHFbn 0.8 -8% US -9% 0.6 International -2% 0.4 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 598m Decline due to COVID-19 impact CER=Constant Exchange Rates 172
Slide 173: Ronapreve (casirivimab/imdevimab)
Ronapreve (casirivimab/imdevimab) Global sales CER growth Regional sales CER growth CHFbn n/a 0.8 0.6 Europe n/a 0.4 0.2 International n/a 0.0 HY 18 HY 19 HY 20 HY 21 HY 2021 sales of CHF 595m • Europe: Government sales mainly in Germany, Italy, France CER=Constant Exchange Rates 173
Slide 174: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 174
Slide 175: HY 2021: Diagnostics Division CER growth by region and customer area
HY 2021: Diagnostics Division CER growth By Region and Customer Area (vs. 2020) Global EMEA¹ North America Asia-Pacific Latin America % CER % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth CHFm growth Core Lab2 3,726 34 1,332 30 677 23 1,465 40 252 51 Molecular Lab 2,216 45 86
Slide 176: Diagnostics Division quarterly sales and CER growth
Diagnostics Division quarterly sales and CER growth1 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Core Lab2 1,439 -17 1,666 -3 1,707 -2 1,765 31 1,961 36 Molecular Lab 944 91 1,020 109 1,182 125 1,107 86 1,109 19 Point of Care 170 -10 181 12 538 212 716 281 90
Slide 177: HY 2021: Diagnostics Division regional sales
HY 2021: Diagnostics Division regional sales Growth driven by EMEA and Asia Pacific Sales YTD CHFm & % of total sales Sales growth at CER Total YTD Sales = 9,042 Diagnostics Division 51% GLOBAL 550 / 70% EMEA* 6% 25% NA 44% ASIA-PAC 2,293 / 4,144 / 77% LAM 25% 46% 2,055 / 23% EMEA* NA ASIA-PAC LAM C
Slide 178: Core Lab
Core Lab 2021 vs. 2020 CHF bn CER growth +34% 4.0 3.5 +23% 3.0 +25% 2.5 2.0 1.5 +40% 1.0 0.5 0.0 HY 2019 HY 2020 HY 2021 Immunodiagnostics Clinical Chemistry Other CER=Constant Exchange Rates 178
Slide 179: Molecular Lab
Molecular Lab 2021 vs. 2020 CHF bn CER growth +45% 2.4 2.2 2.0 +43% 1.8 1.6 +32% 1.4 +14% 1.2 +44% 1.0 +8% 0.8 0.6 0.4 +60% 0.2 0.0 HY 2019 HY 2020 HY 2021 Virology Blood Screening MD Systems Microbiology Cervical Cancer Other CER=Constant Exchange Rates 179
Slide 180: Pathology Lab
Pathology Lab 2021 vs. 2020 CHF bn CER growth +20% 0.7 0.6 +15% 0.5 +23% 0.4 0.3 +20% 0.2 0.1 0.0 HY 2019 HY 2020 HY 2021 Advanced Staining Primary Staining Companion Diagnostics CER=Constant Exchange Rates 180
Slide 181: Diabetes Care
Diabetes Care 2021 vs. 2020 CHF bn CER growth +10% 1.2 1.0 -12% 0.8 +13% 0.6 0.4 0.2 0.0 HY 2019 HY 2020 HY 2021 Blood Glucose Monitoring Other CER=Constant Exchange Rates 181
Slide 182: Point of Care
Point of Care 2021 vs. 2020 CHF bn CER growth +349% 1.8 1.6 -10% 1.4 1.2 +14% 1.0 >500% 0.8 0.6 0.4 0.2 0.0 HY 2019 HY 2020 HY 2021 Other Coagulation & Urinalysis Hospital Glucose Clinical Chemistry & Immunodiagnostics CER=Constant Exchange Rates; Other sales category (HY 2019) represents sales reco
Slide 183: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 183
Slide 184: Exchange rate impact on sales growth
Exchange rate impact on sales growth Negative impact due to most currencies and driven by the USD +0.2p +0.6p -3.1p CER CHF sales growth -0.5p -0.4p sales growth -0.1p -0.1p HY 2021 HY 2021 vs. vs. HY 2020 +8.3% HY 2020 +4.9% CER EUR APAC USD LATAM JPY Other Other CHF Europe CER = Constant Exchange
Slide 185: CHF/USD
CHF/USD Monthly averages 1.00 0.90 -3% -5% 0.80 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 Q H Q Year-To-Date averages F 1.00 0.90 -7% -6% 0.80 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 185
Slide 186: CHF/USD
CHF/USD 1.00 HY 2021 -3% 0.98 0.96 0.94 0.92 0.90 0.88 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg full year 2020 avg full year 2021 monthly avg 2020 monthly avg 2021 186
Slide 187: CHF/EUR
CHF/EUR Monthly averages 1.13 2% 1.08 4% 1.03 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Y 2020 2021 Q H Year-To-Date averages Q 1.13 F 2% 3% 1.08 1.03 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 187
Slide 188: CHF/EUR
CHF/EUR 1.13 HY 2021 2% 1.11 1.09 1.07 1.05 1.03 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg full year 2020 avg full year 2021 monthly avg 2020 monthly avg 2021 188
Slide 189: Average CHF Exchange Rates
Average CHF Exchange Rates HY 2021 HY 2020 HY 2021 vs. HY 2020 USD 0.91 0.97 -6% EUR 1.09 1.06 3% JPY 0.84 0.89 -6% -10% -5% 0% 5% 10% 189
Slide 190: Exchange rate impact on sales growth HY 2021
Exchange rate impact on sales growth HY 2021: negative impact of USD and JPY, positive impact of EUR Development of average exchange rates versus prior year period CHF / USD -6.6% -6.1% CHF / EUR 2.1% 2.8% CHF / JPY -3.8% -5.5% Difference in CHF / CER -4.3% -3.4% growth 8.3% 4.9% 2.9% Sales growth 2
Slide 191: Exchange rate impact on sales growth Q2 2021
Exchange rate impact on sales growth Q2 2021: negative impact of USD and JPY, positive impact of EUR Development of average exchange rates versus prior year period CHF / USD -6.6% -5.5% CHF / EUR 2.1% 3.5% CHF / JPY -3.8% -7.5% Difference in CHF / CER -4.3% -2.4% growth 14.0% 11.6% Sales 2.9% growth
Slide 192: Appendix: Pipeline summary
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Spark Roche Group HY 2021 results Diagnostics Foreign exchange rate information Appendix 192
Slide 193: Pharma growth dynamic excl. AHR improving
Pharma growth dynamic excl. AHR* improving CHFm Quarterly sales development Pharmaceuticals Division (Excl. AHR) 10,000 9,000 8,000 7,000 Pharma other Infectious diseases 6,000 Ophthalmology 5,000 Immunology 4,000 Hemophilia A 3,000 Neuroscience 2,000 Oncology 1,000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 194: Infectious diseases: SARS-CoV-2 development program
Infectious diseases: SARS-CoV-2 development program FDA EUA for Actemra; Positive Ph II interim results for AT-527* • Ronapreve: Positve Ph III (RECOVERY) results show a 20% reduction in the risk of death for patients who do not mount their own antibody response against SARS-CoV-2; Rolling filings f
Slide 195: Tecentriq and tiragolumab: Pivotal read-outs in 2022
Tecentriq and tiragolumab: Pivotal read-outs in 2022 Adjuvant program & new combinations 195
Slide 196: SARS-CoV-2 Rapid Antigen Self Test Nasal (CE)
SARS-CoV-2 Rapid Antigen Self Test Nasal (CE) Patient self-testing for SARS-CoV-2 • Provides patients with the option to self-collect their nasal sample from the front area of the nose • Less invasive testing experience for patients • Detecting all known variants • Instrument-free results in 15 minu
Slide 197: cobas SARS-CoV-2 assay on the cobas Liat System
cobas® SARS-CoV-2 assay on the cobas® Liat® System First 20 min PoC PCR test to receive EUA for asymptomatic screening asymptomatic or symptomatic sample collection ORF 1a/b N SARS-CoV-2 genome • Detects all reported SARS-CoV-2 variants as assessed by Roche's ongoing surveillance program • Running o
Slide 198: Doing now what patients need next
Doing now what patients need next